Read more at
GSK Consumer’s (GSK) Q3FY17 revenue (down 11.7% YoY) came in line, while EBITDA (down 9.5%) and PAT (down 8.3%) slightly surpassed our estimates. Domestic health food drinks’ (HFD) and overall company volumes plummeted 17% YoY. Outlook In our view, this also reflects increased competition from Patanjali Powervita, Sri Ojasvita, and substitutes such as Hershey’s syrup. Gross margin fell 93bps YoY as commodity prices (especially milk, sugar) have started inching up. A&P spends remained soft yet again—down 26.1% and 213bps YoY as the percentage of sales. Maintain ‘HOLD’.
No comments:
Post a Comment